Open-label Access to Dolutegravir for HIV-1 Infected Children and Adolescents Completing IMPAACT Study P1093

Trial Profile

Open-label Access to Dolutegravir for HIV-1 Infected Children and Adolescents Completing IMPAACT Study P1093

Recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Dolutegravir (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Sponsors ViiV Healthcare
  • Most Recent Events

    • 08 Aug 2017 Planned number of patients changed from 40 to 80.
    • 08 Aug 2017 Planned primary completion date changed from 12 Apr 2019 to 29 Dec 2023.
    • 08 Aug 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top